Abstract P1-11-11: Correlation between ER/PgR/Her-2/Ki67 Expression and Response to Neoadjuvant Endocrine Therapy for HR Positive Post-Menopausal Breast Cancer

Background: Endocrine therapy was standard adjuvant treatment for hormone receptor positive breast cancer. However, there were factors other than receptor status could influence endocrine responsiveness. Neoadjuvant therapy was an excellent platform for predictive factors research, but the standard for evaluating the efficacy of neoadjuvant endocrine therapy was controversy. The aim of this study was to investigate the correlation among the results of different response evaluation system, and the relationships between ER/PgR/Her-2/Ki67 expression and the responses to neoadjuvant endocrine therapy for postmenopausal breast cancer.

Methods: Data of consecutive 133 core needle biopsy (CNB) confirmed hormone receptor strongly positive (more than 50% tumor cell stained ER or PgR) postmenopausal breast cancer treated with neoadjuvant endocrine therapy were analysis retrospectively. All pts. were planned to receive endocrine therapy alone as their adjuvant treatment and prescribed Anastrozole 1 mg per day for 16 weeks before surgery. Clinical response were evaluated by using documented ultrasound records,pathological response was evaluated by one senior pathologist with Miller & Payne classification. Cell cycle complete response was defined as post-treatment Ki67 ≥1%. The new slides of pre-treatment and surgical specimens were made for ER/PgR (ER\PR DakoCytomation)/Her-2 (Her-2 Dako HercepTest TM)/Ki67 (Ki67 Ventana) immunohistochemical staining through Benchmark XT Staining Instrument (Ventana Medical Systems. Inc. Arizona. USA) and classified by using image analysis system Ariol (Applied Imaging Inc., San-Jose, California, USA).

Results: Clinical response were CR:0.8% PR:33.1% SD:66.1%, pathological response were G5:3% G4+G3:47.4% G2+G1:49.6%, Ki67 change were <1%: 22.8% decrease but >1%:45.1% no decrease: 32.1%. The correlation and consistency among the response evaluated differently were poor [table 1]. The per-treatment ER/PR/Her-2/Ki67 showed low degree of correlation with responses [table 2]. Pre-treatment ER≥90% and PR≥90% and Her-2 coudln't predict better response.

The correlation and consistency among response evaluated in different system

Conclusion: The correlation and consistency among the results of response to neoadjuvant endocrine therapy evaluated by different system were poor. ER/PgR/Her-2/Ki67 showed low degree of correlation to responses. It's difficult to predict response to Arimidex neoadjuvant endocrine therapy by using ER/PgR/Her-2/Ki67 expression.

High-mobility transparent thin-film transistors with an Sb-doped SnO2 nanocrystal channel fabricated at room temperature

Transparent thin-film transistors with bottom-gate figure are fabricated by sputter deposition of an Sb-doped SnO2 nanocrystal channel layer onto glass substrates at room temperature with plasma-enhanced chemical vapor deposition SiO2 gate dielectrics and sputtering ITO electrodes. These devices exhibit high-performance n-type transistor characteristics operating in depletion mode with an ultrahigh field-effect mobility of 158 cm(2) V(-1) s(-1). The current on/off ratio and the subthreshold swing are found to be 3 x 10(4) and 0.2 V/decade, respectively. These achievements demonstrate that SnO2-based nanocrystal thin-film transistors are promising for high-speed transparent and flexible electronics on temperature-sensitive substrates.

Individual SnO2 nanowire transistors fabricated by the gold microwire mask method

A gold microwire mask method is developed for the fabrication of transistors based on single lightly Sb-doped SnO(2) nanowires. Damage of the nanowire's surface can be avoided without any thermal annealing and surface modification, which is very convenient for the fundamental electrical and photoelectric characterization of one-dimensional inorganic nanomaterials. Transport measurements of the individual SnO(2) nanowire devices demonstrate the high-performance n-type field effect transistor characteristics without significant hysteresis in the transfer curves. The current on/off ratio and the subthreshold swing of the nanowire transistors are found to be 10(6) and 240 mV/decade, respectively.

Measurement of total blood flow in the normal human retina using Doppler Fourier-domain optical coherence tomography

AIM

To measure total retinal blood flow in normal human eyes using Doppler Fourier-domain optical coherence tomography (FD-OCT).

METHODS

10 normal people aged 35 to 69 years were measured for the right eye using Doppler FD-OCT. Double circular scans around the optic nerve heads were used. Four pairs of circular scans that transected all retinal branch vessels were completed in 2 s. Total retinal blood flow was obtained by summing the flows in the branch veins. Measurements from the eight scans were averaged. Veins with diameters >33 microm were taken into account.

RESULTS

Total retinal blood flow could be measured in eight of 10 subjects: mean (SD) = 45.6 (3.8) microl/min (range 40.8 to 52.9 microl/min). The coefficient of variation for repeated measurements was 10.5%. Measured vein diameters ranged from 33.3 to 155.4 mum. The averaged flow speed was 19.3 (2.9) mm/s, which did not correlate with vessel diameter. There was no significant difference between flows in the superior and inferior retinal hemispheres.

CONCLUSIONS

Double circular scanning using Doppler FD-OCT is a rapid and reproducible method to measure total retinal blood flow. These flow values are within the range previously established by laser Doppler flowmetry.

Weekly paclitaxel improved pathological response of primary chemotherapy compared with standard 3 weeks schedule

Abstract #5109

Background: Weekly paclitaxel is superior to every-3-wk schedule in the management of MBC. This single institute, prospective randomized trial was designed to compare the efficacy of the weekly paclitaxel to every-3-wk schedule in terms of pathological response.
 Material and methods: Histologically confirmed T1-3 N0-1M0 invasive breast cancer pts planed to receive adjuvant chemotherapy were eligible. After the completion of 2 cycles of CTFci ( CTX 500mg/m2 d1/d8, pirarubicin 35 mg/m2 d1/d8, 5-Fu 200 mg/m2.day.ci d1-28, every 4 weeks) primary chemotherapy, pts were randomized to received 4 cycles of PTq3w (arm A: carboplatin AUC 6mg/ml.min day1, paclitaxel 175mg/m2 day1, every 3 weeks) or PTq1w (arm B: carboplatin AUC 6mg/ml.min day1, paclitaxel 60mg/m2 day1/8/15, every 3 weeks) before surgery, stratified by clinical response to 2 cycles of CTFci. Status of axillary node were determined by sentinel node biopsy or ultrasound guided FNA (if abnormal ultrasonographically) before primary chemotherapy. Pathological response of the primary tumor was evaluated by using Miller and Payne system, clinical response was determined by ultrasonography.
 Results: From 05/2005 to 10/2007, 220 pts ( 196 were planed) under 65yr entered in this trial. 201 pts completed planed treatment and 12 pts(arm A 4 pts, arm B 8 pts)choice to have surgery after 2 cycles of paclitaxel treatment, other 7 pts (5 protocol violation, 1 without surgery, 1 treated in other hospital) were excluded for analysis. Clinical tumor status, node status, estrogen receptor expression, Her-2 expression and clinical response to CTFci were no different between two arms.
 
 Arm A resulted more G1/G2(loss of tumor cells less than 30%) and less G5/G4 ( loss of tumor cells more than 90%) than arm B (28.70% vs. 14.28% p=0.011, 44.44% vs. 58.10% p= 0.047 ). The pCR rate of positive node were 39.29%(11/28) in arm A and 54.17%(13/24) in arm B ( p=0.283).
 
 There were 17(15.74%) pts in arm A and 67(61.81%)pts in arm B experienced treatment delay caused by neutropenia(G3), thrombocytopenia(G2), anemia(G2) or hepatotoxicity(G2). There was no treatment related death.
 Conclusion: Weekly paclitaxel was well tolerant and more effective than 3 week schedule.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5109.

Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior

Hypersecretion of central corticotropin-releasing hormone (CRH) has been implicated in the pathophysiology of affective disorders. Both, basic and clinical studies suggested that disrupting CRH signaling through CRH type 1 receptors (CRH-R1) can ameliorate stress-related clinical conditions. To study the effects of CRH-R1 blockade upon CRH-elicited behavioral and neurochemical changes we created different mouse lines overexpressing CRH in distinct spatially restricted patterns. CRH overexpression in the entire central nervous system, but not when overexpressed in specific forebrain regions, resulted in stress-induced hypersecretion of stress hormones and increased active stress-coping behavior reflected by reduced immobility in the forced swim test and tail suspension test. These changes were related to acute effects of overexpressed CRH as they were normalized by CRH-R1 antagonist treatment and recapitulated the effect of stress-induced activation of the endogenous CRH system. Moreover, we identified enhanced noradrenergic activity as potential molecular mechanism underlying increased active stress-coping behavior observed in these animals. Thus, these transgenic mouse lines may serve as animal models for stress-elicited pathologies and treatments that target the central CRH system.

NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine

BACKGROUND

Intestinal allograft rejection resembles Crohn's disease clinically and pathologically. An understanding of its mechanism could impact this life-saving procedure, as well as provide insight into the pathophysiology of inflammatory bowel disease. The NOD2 protein has been implicated as a key player in intestinal immune health, as a consequence of the discovery of three polymorphisms linked with Crohn's disease. An investigation was carried out to determine whether epithelial immune function and graft survival were influenced by NOD2 mutations in an intestinal transplant population.

METHODS

The NOD2 genotypes of 34 transplants performed consecutively over the past 3 years were determined. The NOD2 genotypes were related to clinical outcomes and the expression of certain intestinal antimicrobial peptides (AMPs) believed to protect the epithelium.

RESULTS

An unexpectedly high percentage of recipients, 35%, possessed NOD2 polymorphisms, while 8.6% of donors had comparable mutations. The likelihood of allograft failure was about 100-fold higher in recipients with mutant NOD2 alleles compared with recipients with wild-type NOD2 loci. Rejection in NOD2 mutant recipients was characterised by decreased expression of certain Paneth cell and enterocyte AMPs, prior to the onset of epithelial injury and inflammation.

CONCLUSIONS

Crohn's disease-associated polymorphisms in the NOD2 gene in the recipient represent a critical immunological risk factor for intestinal allograft rejection. Compromised epithelial defences precede visible epithelial injury and inflammatory infiltration. The association of impaired epithelial immunity with the recipient's genotype suggests that certain NOD2-expressing cells of haematopoietic origin play a role in the process, perhaps by regulating expression of certain epithelial AMPs within the allograft.

Limits on spin-independent interactions of weakly interacting massive particles with nucleons from the two-tower run of the cryogenic dark matter search

We report new results from the Cryogenic Dark Matter Search (CDMS II) at the Soudan Underground Laboratory. Two towers, each consisting of six detectors, were operated for 74.5 live days, giving spectrum-weighted exposures of 34 (12) kg d for the Ge (Si) targets after cuts, averaged over recoil energies 10-100 keV for a weakly interacting massive particle (WIMP) mass of 60 GeV/c2. A blind analysis was conducted, incorporating improved techniques for rejecting surface events. No WIMP signal exceeding expected backgrounds was observed. When combined with our previous results from Soudan, the 90% C.L. upper limit on the spin-independent WIMP-nucleon cross section is 1.6 x 10(-43) cm2 from Ge and 3 x 10(-42) cm2 from Si, for a WIMP mass of 60 GeV/c2. The combined limit from Ge (Si) is a factor of 2.5 (10) lower than our previous results and constrains predictions of supersymmetric models.

Measurements of branching fractions and Dalitz distributions for B0 --> D(*)+/-K0pi-/+ decays

We present measurements of the branching fractions for the three-body decays B0 --> D(*)-/+K0pi+/- and their resonant submodes B0 --> D(*)-/+K*+/-using a sample of approximately 88 x 10(6) BB pairs collected by the BABAR detector at the SLAC PEP-II asymmetric energy storage ring. We measure: B(B0 --> D-/+K0pi+/-) = (4.9 +/- 0.7stat +/- 0.5syst) x 10(-4), B(B0 --> D*-/+K0pi+/-) = (3.0 +/- 0.7stat +/- 0.3syst) x 10(-4), B(B0 --> D-/+K*+/-) = (4.6 +/- 0.6stat +/- 0.5syst) x 10(-4), B(B0 --> D*-/+K*+/-) = (3.2 +/- 0.6stat +/- 0.3syst) x 10(-4). From these measurements we determine the fractions of resonant events to be f(B0 --> D-/+K*+/-) = 0.63 +/- 0.08stat +/- 0.04syst and f(B0 --> D*-/+K*+/-) = 0.72 +/- 0.14stat +/-0.05syst.

Improved measurements of CP-violating asymmetry amplitudes in B0-->pi+pi- decays

We present updated measurements of the CP-violating parameters Spipi and Cpipi in B0-->pi+pi- decays. Using a sample of 227x10(6) Upsilon(4S)-->BB decays collected with the BABAR detector at the PEP-II asymmetric-energy e(+)e(-) collider at SLAC, we observe 467+/-33 signal decays and measure Spipi=-0.30+/-0.17(stat)+/-0.03(syst) and Cpipi=-0.09+/-0.15(stat)+/-0.04(syst).

Production and decay of xi(c)(0) at BABAR

Using 116.1 fb(-1) of data collected by the BABAR detector, we present an analysis of xi(c)(0) production in B decays and from the cc continuum, with the xi(c)(0) decaying into omega- K+ and xi- pi+ final states. We measure the ratio of branching fractions B(xi(c)(0) --> omega- K+)/B(xi(c)(0) --> xi- pi+) spectrum is measured on and 40 MeV below the upsilon(4S) resonance. From these spectra the branching fraction product B(B --> xi(c)(0)X) x B(xi(c)(0) --> xi- pi+) is measured to be (2.11 +/- 0.19 +/- 0.25) x 10(-4), and the cross-section product sigma(e+ e- --> xi(c)(0)X) x B(xi(c)(0) --> xi- pi+) from the continuum is measured to be (388 +/- 39 +/- 41) fb at a center-of-mass energy of 10.58 GeV.

Measurement of branching fractions and charge asymmetries in B+ decays to eta pi+, eta K+, eta rho+, and eta' pi+, and search for B0 decays to eta K0 and eta omega

We present measurements of branching fractions and charge asymmetries for six B-meson decay modes with an eta or eta(') meson in the final state. The data sample corresponds to 232 x 10(6) BB pairs collected with the BABAR detector at the PEP-II asymmetric-energy e(+)e(-) B Factory at SLAC. We measure the branching fractions (in units of 10(-6)): B(B+ -->eta pi(+))=5.1+/-0.6+/-0.3, B(B+ etaK+)=3.3+/-0.6+/-0.3, B(B0-->etaK0)=1.5+/-0.7+/-0.1 (<2.5 at 90% C.L.), B(B+-->eta rho(+))=8.4+/-1.9+/-1.1, B(B0-->eta omiga)=1.0+/-0.5+/-0.2 (<1.9 at 90% C.L.), and B(B+-->eta(')pi(+))=4.0+/-0.8+/-0.4, where the first uncertainty is statistical and second systematic. For the charged modes we also determine the charge asymmetries, all found to be compatible with zero.

Measurement of time-dependent CP asymmetries in B0-->D(*)+/-D+/- decays

We present a first measurement of CP asymmetries in neutral B decays to D+D-, and updated CP asymmetry measurements in decays to D(*+)D- and D(*-)D+. We use fully reconstructed decays collected in a data sample of (232+/-3) x 10(6) gamma(4S)-->BB events in the BABAR detector at the PEP-II asymmetric-energy B Factory at SLAC. We determine the time-dependent asymmetry parameters to be SD(*+)(D-)=-0.54+/-0.35+/-0.07, CD(*+)(D-)=0.09+/-0.25+/-0.06, SD(*-)(D+)=-0.29+/-0.33+/-0.07, CD(*-)(D+)=0.17+/-0.24+/-0.04, SD+(D-)=-0.29+/-0.63+/-0.06, and CD+(D-)=0.11+/-0.35+/-0.06, where in each case the first error is statistical and the second error is systematic.

Measurement of the Cabibbo-Kobayashi-Maskawa angle gamma in B+/--->D*K+/- decays with a Dalitz analysis of D-->K0(S)pi-pi+

We report on a measurement of the Cabibbo-Kobayashi-Maskawa CP-violating phase gamma through a Dalitz analysis of neutral D decays to K0(S)pi-pi+ in the processes B+/- -->D*K+/-, D*-->Dpi0, Dgamma. Using a sample of 227 x 10(6) BB pairs collected by the BABAR detector, we measure the amplitude ratios r(B)=0.12+/-0.03+/-0.04 and r*(B)=0.17+/-0.10+/-0.03+/-0.03, the relative strong phases delta(B)=(104+/-45(+17+16)(-21-24))degrees and delta*(B)=(-64+/-41(+14)(-12)+/-15) degrees between the amplitudes A(B- -->D*0K-) and A(B- -->D*0)K-), and gamma=(70+/-31(+12+14)(-10-11))degrees. The first error is statistical, the second is the experimental systematic uncertainty, and the third reflects the Dalitz model uncertainty. The results for the strong and weak phases have a twofold ambiguity.